Novo Nordisk appoints global research head days before investor update
A new research chief takes over Novo Nordisk's discovery work as the maker of Ozempic and Wegovy faces a sales warning and generic competition later this decade.
Novo Nordisk has appointed a new global head of research, placing a new leader over its drug discovery work days before the company's Sept. 15 employee town hall and its Sept. 21 capital markets day [1][2].
The appointment came in the days before those meetings, reported together with news that Takeda's research and development chief, Andy Plump, is retiring [1]. Novo Nordisk has not disclosed the name of the new research head, when the role takes effect, or what the job will cover [1]. The company also has not said whether the appointment changes any specific drug program [1].
Employees were invited to a Sept. 15 town hall described in the invitation as a Tuesday afternoon session to "share an exciting update about our company's next chapter," according to a copy seen by Bloomberg [2]. A spokesperson said the internal meeting is set for before Novo's Sept. 21 capital markets day [2].
The backdrop is a difficult stretch for Novo's pipeline and its stock. In July, an experimental injection intended to lower cardiovascular risk failed in a large trial, and the company halted two additional major studies of the same drug; a fourth trial of that drug was expected to report next year [2]. On Friday, Sept. 11, shares in Copenhagen fell as much as 3.3% and were down 14% for the year, after early enthusiasm about Wegovy's momentum gave way to questions about the company's longer-term trajectory [2].
Novo has warned that profit and sales could fall by as much as 6% this year, even with demand for its new Wegovy pill [2]. Morgan Stanley's Thibault Boutherin downgraded the shares on Friday, flagging the company's heavy dependence on Ozempic and Wegovy [2]. Both brands use semaglutide as their active ingredient, and both injections are projected to face lower-cost generics in Europe and the US by the early 2030s [2]. Boutherin said sales of the pill version could reach $10 billion by 2031 but argued that would not be enough to blunt mounting competition [2].
CEO Mike Doustdar is under pressure to show that his plan to sharpen Novo's competitive edge is taking hold [2]. The research appointment is one of the few concrete personnel moves reported so far, and the company has not said how it fits into a broader reorganization [1][2].
Why it matters for patients
An executive appointment does not change the approval status, label, supply or insurance coverage of any medicine on the market today [1][2]. Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) are not affected by who runs Novo's research organization.
What research leadership can shape is what comes later. The July failure stopped one experimental cardiovascular injection and two related studies, and the company has not said what, if anything, will replace it in that program [2]. For patients waiting on new options in that area, no timeline has been reported [2].
Cost is a separate thread. Novo's own reported projections have lower-cost generic versions of the semaglutide injections arriving in Europe and the US by the early 2030s [2]. That is a forecast about timing, not a commitment, and no generic semaglutide injection is described as available now [2].
What happens next
Sept. 15: Novo Nordisk holds an internal town hall for employees [2].
Sept. 21: The company holds a capital markets day for investors [2].
Next year: A fourth trial of the experimental cardiovascular injection is expected to report results [2].
The name of the new global research head has not been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.